Nothing Special   »   [go: up one dir, main page]

IN2012DN03928A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03928A
IN2012DN03928A IN3928DEN2012A IN2012DN03928A IN 2012DN03928 A IN2012DN03928 A IN 2012DN03928A IN 3928DEN2012 A IN3928DEN2012 A IN 3928DEN2012A IN 2012DN03928 A IN2012DN03928 A IN 2012DN03928A
Authority
IN
India
Prior art keywords
fmdv
vaccine
methods
well
substypes
Prior art date
Application number
Other languages
English (en)
Inventor
David B Weiner
Bernadette Ferraro
Jian Yan
Patricia A Brown
Rodney A Bowling
Douglas R Kern
Mathura P Ramanathan
Niranjan Y Sardesai
Karuppiah Muthumani
Original Assignee
Univ Pennsylvania
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Inovio Pharmaceuticals Inc filed Critical Univ Pennsylvania
Publication of IN2012DN03928A publication Critical patent/IN2012DN03928A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
    • G01N2333/09—Foot-and-mouth disease virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medical Informatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
IN3928DEN2012 2009-11-02 2010-11-02 IN2012DN03928A (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25746109P 2009-11-02 2009-11-02
US25745009P 2009-11-02 2009-11-02
PCT/US2010/055187 WO2011054011A2 (en) 2009-11-02 2010-11-02 Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom

Publications (1)

Publication Number Publication Date
IN2012DN03928A true IN2012DN03928A (de) 2015-09-04

Family

ID=43923082

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3928DEN2012 IN2012DN03928A (de) 2009-11-02 2010-11-02

Country Status (11)

Country Link
US (5) US9109014B2 (de)
EP (1) EP2498814B1 (de)
JP (6) JP2013509203A (de)
KR (5) KR101851699B1 (de)
CN (2) CN106987595B (de)
AU (1) AU2010313132B2 (de)
BR (1) BR112012010357B1 (de)
CA (3) CA3030893C (de)
IN (1) IN2012DN03928A (de)
MX (1) MX2012004967A (de)
WO (1) WO2011054011A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN03928A (de) 2009-11-02 2015-09-04 Univ Pennsylvania
CN102260750B (zh) * 2011-07-20 2013-06-05 东莞出入境检验检疫局检验检疫综合技术中心 用于口蹄疫病毒实时荧光rt-pcr检测的引物和方法
JP2013050356A (ja) * 2011-08-30 2013-03-14 National Agriculture & Food Research Organization 抗体を用いて口蹄疫ウイルスを検出する方法
CN102702349B (zh) * 2012-05-15 2013-11-20 中国农业科学院兰州兽医研究所 抗口蹄疫AsiaI型病毒的双峰驼VHH重链抗体及其制备方法和用途
US10058078B2 (en) 2012-07-31 2018-08-28 Recombinetics, Inc. Production of FMDV-resistant livestock by allele substitution
WO2014039014A1 (en) * 2012-09-07 2014-03-13 Agency For Science, Technology And Research Peptides and their uses
KR101535555B1 (ko) * 2012-12-24 2015-07-10 대한민국 구제역 바이러스 Ｏ Ｍａｎｉｓａ를 이용한 재조합 구제역 백신 바이러스
RU2522868C1 (ru) * 2013-03-06 2014-07-20 Федеральное государственное унитарное предприятие "Щелковский биокомбинат" Способ изготовления вакцины против ящура
KR102276405B1 (ko) * 2013-03-15 2021-07-12 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 구제역 바이러스 (fmdv) 공통 단백질, 그에 대한 코딩 서열 및 그로부터 제조된 백신
WO2014154655A1 (en) 2013-03-26 2014-10-02 The Pirbright Institute Stabilised fmdv capsids
CN103554234B (zh) * 2013-09-05 2016-01-27 广西壮族自治区动物疫病预防控制中心 基于口蹄疫a型vp1蛋白及其单抗的竞争elisa方法
CN105624124B (zh) * 2014-11-07 2020-09-29 普莱柯生物工程股份有限公司 一种抗o型口蹄疫的疫苗组合物及其制备方法和应用
WO2017147458A1 (en) * 2016-02-25 2017-08-31 The Trustees Of The University Of Pennsylvania Novel vaccines against zika virus
BR112018070634A2 (pt) * 2016-04-11 2019-02-05 Biogenesis Bago Hong Kong Ltd vacina universal para doenças virais
CN105861755B (zh) * 2016-06-07 2019-03-29 中国农业科学院兰州兽医研究所 用于快速检测南非型口蹄疫病毒的特异性引物组及包含有该引物组的试剂盒
US10172933B2 (en) * 2016-10-31 2019-01-08 The United States Of America, As Represented By The Secretary Of Agriculture Mosaic vaccines for serotype a foot-and-mouth disease virus
US20190275138A1 (en) * 2016-11-22 2019-09-12 The Wistar Institute Of Anatomy And Biology Foot and mouth disease virus serotype o (fmdv-o) vaccine
AU2018298499B2 (en) * 2017-07-03 2024-07-18 Bharat Biotech International Limited A synthetic polypeptide epitope based vaccine composition
KR102165358B1 (ko) * 2017-12-29 2020-10-14 (주)플럼라인생명과학 구제역 바이러스 a형 백신 조성물
WO2020067027A1 (ja) * 2018-09-28 2020-04-02 一般財団法人阪大微生物病研究会 Ｖｌｐ発現ｃｈｏ細胞株の構築
KR102285977B1 (ko) * 2019-03-15 2021-08-05 대한민국 오일 에멀젼과 병용 투여 가능한 면역증강용 보조물질 및 이를 포함하는 구제역 백신 조성물
WO2020263062A1 (ko) * 2019-06-28 2020-12-30 (주)플럼라인생명과학 구제역 바이러스 백신 조성물
CN113897392B (zh) * 2020-07-06 2024-07-02 嘉兴安宇生物科技有限公司 一种口蹄疫的三价重组腺病毒疫苗及其构建方法
KR102513632B1 (ko) * 2021-11-30 2023-03-28 주식회사 왓슨알앤디 구제역 바이러스 유사 입자를 생산하기 위한 백신 플랫폼
CN117304271B (zh) * 2023-09-27 2024-04-16 中国农业科学院兰州兽医研究所 一种o型口蹄疫病毒vp2蛋白t细胞表位多肽及其应用

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US5643579A (en) 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US4790987A (en) 1985-11-15 1988-12-13 Research Corporation Viral glycoprotein subunit vaccine
US5310668A (en) 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
AT400955B (de) 1989-03-08 1996-05-28 Health Research Inc Rekombinantes pockenvirus-wirtsselektionssystem
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
ATE138784T1 (de) 1989-03-31 1996-06-15 Univ Washington Impfstoffe enthaltende avirulente phop-type mikroorganismen
ES2070997T3 (es) 1989-12-04 1995-06-16 Akzo Nobel Nv Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos.
US5294548A (en) 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
AU7906691A (en) 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
US5462734A (en) 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
NZ262582A (en) 1993-01-26 1997-10-24 David B Weiner Compositions and methods for delivery of genetic material
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
AU700371B2 (en) 1993-06-07 1999-01-07 Genentech Inc. Hiv envelope polypeptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US6156319A (en) 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
NL9401820A (nl) 1994-11-02 1996-06-03 Meyn Maschf Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte.
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5650309A (en) 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US5698202A (en) 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
AU733628B2 (en) 1997-04-03 2001-05-17 Electrofect As Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
EP0991426B2 (de) 1997-06-30 2007-03-28 Institut Gustave Roussy Verabreichung der nukleinsäure in den quergestreiften muskel
US6107021A (en) 1998-06-20 2000-08-22 United Biomedical, Inc. Synthetic peptide vaccines for foot-and-mouth disease
EP2428250A1 (de) 1998-07-13 2012-03-14 Genetronics, Inc. Haut- und muskelgerichtete Gentherapie mit hilfe eines gepulsten elektrischen Felds
US6589529B1 (en) 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
AU3274500A (en) 1999-03-18 2000-10-09 Exiqon A/S Detection of mutations in genes by specific lna primers
JP3543326B2 (ja) 2001-08-30 2004-07-14 ソニー株式会社 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
US20040175727A1 (en) 2002-11-04 2004-09-09 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
US7517520B2 (en) * 2003-03-26 2009-04-14 Cytos Biotechnology Ag Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
WO2004094595A2 (en) 2003-04-17 2004-11-04 Alnylam Pharmaceuticals Inc. MODIFIED iRNA AGENTS
CA2567324C (en) 2003-05-30 2012-01-03 Advisys, Inc. Devices and methods for biomaterial production
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
CN1290579C (zh) * 2003-10-15 2006-12-20 北京迪威华宇生物技术有限公司 重组口蹄疫病毒vp1融合蛋白疫苗
CN1275649C (zh) * 2003-11-07 2006-09-20 复旦大学 抗o型和a型口蹄疫病毒双价多肽疫苗及其制备方法
US20050182005A1 (en) 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
ES2424847T3 (es) 2004-06-25 2013-10-09 Merial Ltd. Genes del virus de la fiebre aftosa que expresan avipox recombinantes
JP4595408B2 (ja) 2004-07-08 2010-12-08 パナソニック株式会社 圧縮機
CN1737144A (zh) 2004-08-18 2006-02-22 金宁一 口蹄疫复合多表位二价核酸疫苗的构建
CA2591532A1 (en) * 2004-09-03 2006-03-09 Consejo Superior De Investigaciones Cientificas Nucleic acid sequences encoding proteins capable of associating into a virus-like particle
EP1632247A1 (de) 2004-09-03 2006-03-08 Consejo Superior De Investigaciones Cientificas Nukleinsäuren, die für FMDV Proteine kodieren und, die in virus-ähnliche Partikel assemblieren können
EP3312272B1 (de) * 2004-10-08 2019-08-28 The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services Modulation der replikationsrate durch verwendung von seltener verwendeten synonymen kodonen
WO2006063445A1 (en) 2004-12-14 2006-06-22 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Recombinant foot and mouth disease vaccine
CN101121938B (zh) * 2007-03-23 2010-10-06 中国农业科学院兰州兽医研究所 一种口蹄疫抗原的制备方法
CN100572541C (zh) * 2007-05-28 2009-12-23 中国农业科学院兰州兽医研究所 口蹄疫病毒双效疫苗载体、其制备方法及应用
AU2008331673B2 (en) * 2007-11-12 2014-12-11 The Trustees Of The University Of Pennsylvania Novel vaccines against multiple subtypes of influenza virus
CN101270155B (zh) 2008-05-06 2011-04-27 中国农业科学院兰州兽医研究所 通过耐酸性改造在昆虫中组装口蹄疫病毒空衣壳的方法
ES2344875B1 (es) * 2008-05-27 2011-06-29 Consejo Superior De Investigaciones Cientificas (Csic) (70%) Vacuna atenuada para la fiebre aftosa.
IN2012DN03928A (de) 2009-11-02 2015-09-04 Univ Pennsylvania
BR112012023852B1 (pt) 2010-03-12 2020-11-10 Biolex Therapeutics vacinas recombinantes do vírus da língua azul e usos das mesmas
US8765141B2 (en) 2010-07-01 2014-07-01 The United States Of America, As Represented By The Secretary Of Agriculture Development of a marker foot and mouth disease virus vaccine candidate that is attenuated in the natural host
GB201014965D0 (en) 2010-09-08 2010-10-20 Animal Health Inst Vaccine
JP7026380B2 (ja) 2017-10-17 2022-02-28 株式会社吉田製作所 動揺度測定装置、動揺度測定プログラムおよび記録媒体

Also Published As

Publication number Publication date
JP6545731B2 (ja) 2019-07-17
CN106987595B (zh) 2021-07-06
KR101851699B1 (ko) 2018-04-24
US11124545B2 (en) 2021-09-21
JP2013509203A (ja) 2013-03-14
KR20200092416A (ko) 2020-08-03
US9109014B2 (en) 2015-08-18
JP2019213523A (ja) 2019-12-19
US10294278B2 (en) 2019-05-21
US20240360182A1 (en) 2024-10-31
KR20210149203A (ko) 2021-12-08
JP2023100733A (ja) 2023-07-19
MX2012004967A (es) 2012-11-21
CA2777705C (en) 2019-03-12
KR101965337B1 (ko) 2019-04-03
JP2017131223A (ja) 2017-08-03
WO2011054011A3 (en) 2011-08-04
JP7269987B2 (ja) 2023-05-09
US20120282217A1 (en) 2012-11-08
WO2011054011A2 (en) 2011-05-05
WO2011054011A4 (en) 2011-09-22
US20200017553A1 (en) 2020-01-16
US12049479B2 (en) 2024-07-30
BR112012010357B1 (pt) 2022-05-24
CA3030893A1 (en) 2011-05-05
US20220009971A1 (en) 2022-01-13
AU2010313132A1 (en) 2012-05-17
AU2010313132B2 (en) 2015-01-15
JP6085636B2 (ja) 2017-02-22
KR20180042464A (ko) 2018-04-25
EP2498814A4 (de) 2013-11-13
EP2498814B1 (de) 2015-09-09
EP2498814A2 (de) 2012-09-19
US20160039886A1 (en) 2016-02-11
KR20190037367A (ko) 2019-04-05
CN106987595A (zh) 2017-07-28
CN102712931A (zh) 2012-10-03
KR20120114217A (ko) 2012-10-16
KR102138780B1 (ko) 2020-07-29
JP2021121207A (ja) 2021-08-26
BR112012010357A2 (de) 2017-10-03
CA3177356A1 (en) 2011-05-05
CA2777705A1 (en) 2011-05-05
CA3030893C (en) 2022-11-29
JP2015166353A (ja) 2015-09-24

Similar Documents

Publication Publication Date Title
IN2012DN03928A (de)
WO2012106377A3 (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
WO2009105152A3 (en) Virus-like particles as vaccines for paramyxovirus
WO2011094358A9 (en) Influenza nucleic acid molecules and vaccines made therefrom
MX343830B (es) Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.
EP3552622A3 (de) Priming einer immunantwort
HK1125051A1 (en) Virus-like particles as vaccines for paramyxovirus
WO2004080403A3 (en) Influenza virus vaccine
MX346862B (es) Secuencias consenso de envoltura de vih y método para usar las mismas.
WO2008115199A3 (en) Chimeric virus vaccines
EP3199545A3 (de) Rechnerisch optimierte breit reaktive h1n1-influenza-antigene
WO2010057159A3 (en) Antigens that elicit immune response against flavivirus and methods of using same
WO2016100328A8 (en) Novel tilapia virus and uses thereof
WO2007008918A3 (en) Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
WO2013001285A3 (en) Fmdv vp1 peptides
EA202090759A3 (ru) Коровый белок вируса гепатита в и поверхностный антигенный белок и содержащая их вакцина
WO2014145951A3 (en) Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
WO2012047679A8 (en) Consensus antigen constructs and vaccines made therefrom, and methods of using same to treat malaria
WO2015052543A3 (en) Malaria vaccination
MX2022000718A (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9.
MX2015013304A (es) Vacunas de nucleoproteina de la influenza.
AU2013352179A8 (en) Computationally optimized broadly reactive antigens for H1N1 influenza
WO2011038473A8 (pt) Método, kit, plasmídeo e composição para induzir resposta imune contra virus da dengue baseado em vacinas de dna e vírus quiméricos
BR112017024283A8 (pt) Vacinas contra a dengue